Additional file 5: of Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study

Table S3. Duration and amount of HBV medications and interferons in patients who received them in the study period, as grouped according to the use of ACEIs or ARBs within 6Â months after the index date. (DOCX 17Â kb)